Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · bladder-landscape@3

SRR26320072

—

db6f39cf-94eb-5d07-b31a-2c189c1ab8c0

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
—
cancer_type_detailed
—
subtype
—
sex
Male

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • INTERFERON_ALPHA_RESPONSE+0.740
  • INTERFERON_GAMMA_RESPONSE+0.650
  • IL6_JAK_STAT3_SIGNALING+0.500
  • ALLOGRAFT_REJECTION+0.480
  • PROTEIN_SECRETION+0.430
  • INFLAMMATORY_RESPONSE+0.400
  • APOPTOSIS+0.340
  • COMPLEMENT+0.330
  • PI3K_AKT_MTOR_SIGNALING+0.320
  • CHOLESTEROL_HOMEOSTASIS+0.300

Top 10 suppressed

  • MYC_TARGETS_V2-0.530
  • E2F_TARGETS-0.370
  • MYC_TARGETS_V1-0.340
  • WNT_BETA_CATENIN_SIGNALING-0.320
  • G2M_CHECKPOINT-0.290
  • SPERMATOGENESIS-0.210
  • MYOGENESIS-0.120
  • KRAS_SIGNALING_DN-0.100
  • ANGIOGENESIS-0.080
  • HYPOXIA-0.080

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

8 twins match this tumor's tissue · 2 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
1TCGA-44-2656-01A-02R-0946-07
lung-landscapes@6
—cohortA10.878
2TCGA-50-5941-01A-11R-1755-07
lung-landscapes@6
—cohortA10.860
3C3N-02242
lung-landscapes@6
—cohortA10.848
4SRR8518287
breast-umap@18
—C0.846
5bd09bf00-3fb3-41fc-ae4d-4ac68a925a6b
melanoma-umap@29
——0.845
6BS_7Z93ZYMS
brain-umap@2
pilocytic astrocytoma—0.842
7TCGA-05-4425-01A-01R-1755-07
lung-landscapes@6
—cohortA10.833
8DRR168557
bladder-landscape@3
——0.827
9TCGA-EW-A1PE-01A-11R-A144-07
breast-umap@18
—B0.827
10BS_V3REENH9
brain-umap@2
pilocytic astrocytoma—0.826

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 33 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
INTERFERON_ALPHA_RESPONSE0.740Inavolisib— uncovered
INTERFERON_GAMMA_RESPONSE0.650Idelalisib— uncovered
IL6_JAK_STAT3_SIGNALING0.500Inavolisib— uncovered
ALLOGRAFT_REJECTION0.480Idelalisib— uncovered
PROTEIN_SECRETION0.430Remibrutinib— uncovered
INFLAMMATORY_RESPONSE0.400Idelalisib— uncovered
APOPTOSIS0.340Idelalisib— uncovered
COMPLEMENT0.330Inavolisib— uncovered
PI3K_AKT_MTOR_SIGNALING0.320Inavolisib— uncovered
CHOLESTEROL_HOMEOSTASIS0.300Remibrutinib— uncovered
P53_PATHWAY0.270Idelalisib— uncovered
ANDROGEN_RESPONSE0.260Inavolisib— uncovered
HEME_METABOLISM0.210Temsirolimus— uncovered
KRAS_SIGNALING_UP0.210Inavolisib— uncovered
IL2_STAT5_SIGNALING0.190Idelalisib— uncovered
PEROXISOME0.190Idelalisib— uncovered
DNA_REPAIR0.170Idelalisib— uncovered
MTORC1_SIGNALING0.160Inavolisib— uncovered
TNFA_SIGNALING_VIA_NFKB0.150Inavolisib— uncovered
BILE_ACID_METABOLISM0.140Inavolisib— uncovered